Physician profile
Michael Lang
NPI 1205203155
$3,983.17
in general payments reported to CMS, 2019-2025
31 companies · $1,157 in 2025
The $1,157 reported for 2025 was more than what 87% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $23.06 · 2022: $97.94 · 2023: $63.78 · 2024: $2,641 · 2025: $1,157.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,792 · Education: $69.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,792.18 |
| Education | $69.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $438.64 | 2024-2025 | Keytruda, Lynparza, Welireg |
| E.R. Squibb & Sons, L.L.C. | $373.72 | 2024-2025 | Opdivo |
| Novartis Pharmaceuticals Corporation | $343.66 | 2024-2025 | |
| Taiho Oncology, INC. | $241.38 | 2024-2025 | |
| Eisai INC. | $222.25 | 2024-2025 | |
| Astellas Pharma US INC | $203.42 | 2024-2025 | Vyloy, Xospata |
| Abbvie INC. | $192.63 | 2023-2025 | |
| Astrazeneca Pharmaceuticals Lp | $171.23 | 2024-2025 | Lynparza, Calquence |
| Janssen Biotech, INC. | $168.68 | 2024-2025 | Tecvayli, Rybrevant, Erleada |
| Bayer Healthcare Pharmaceuticals INC. | $159.81 | 2024-2025 | |
| Daiichi Sankyo INC. | $149.59 | 2021-2025 | Enhertu |
| Regeneron Healthcare Solutions, INC. | $148.81 | 2024-2025 | Libtayo, Lynozyfic |
| Glaxosmithkline, LLC. | $138.71 | 2024-2025 | Jemperli, Zejula |
| Rigel Pharmaceuticals, INC. | $137.33 | 2024-2025 | Rezlidhia, Tavalisse, Gavreto |
| Karyopharm Therapeutics INC. | $124.09 | 2025 | Xpovio |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $102.98 | 2024 | Empaveli |
| Aveo Pharmaceuticals, INC. | $99.78 | 2024-2025 | |
| Lilly USA, LLC | $83.28 | 2024-2025 | Verzenio, Jaypirca, Retevmo |
| Emd Serono, INC. | $76.85 | 2024-2025 | |
| Route 92 Medical, INC. | $73.26 | 2022 | |
| Mirati Therapeutics, INC. | $60.29 | 2024 | Krazati |
| Pharmacosmos Therapeutics INC. | $55.74 | 2024-2025 | Monoferric |
| Array Biopharma INC | $34.01 | 2024-2025 | Braftovi, Tukysa |
| Alexion Pharmaceuticals, INC. | $32.48 | 2024-2025 | Ultomiris |
| Boston Scientific Corporation | $30.52 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.78 | 2024 | Fruzaqla |
| Incyte Corporation | $21.83 | 2024 | Jakafi |
| Tempus Ai, INC | $20.00 | 2024 | |
| Sobi, INC | $18.98 | 2024 | |
| Stemline Therapeutics INC. | $17.88 | 2025 | Orserdu |
| Jazz Pharmaceuticals INC. | $17.56 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Lang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.